vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and HEALTHY CHOICE WELLNESS CORP. (HCWC). Click either name above to swap in a different company.
HEALTHY CHOICE WELLNESS CORP. is the larger business by last-quarter revenue ($18.7M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -8.9%, a 8.0% gap on every dollar of revenue. HEALTHY CHOICE WELLNESS CORP. produced more free cash flow last quarter ($-927.1K vs $-15.8M).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs HCWC — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $18.7M |
| Net Profit | $-154.0K | $-1.7M |
| Gross Margin | — | 39.1% |
| Operating Margin | -6.9% | -7.6% |
| Net Margin | -0.8% | -8.9% |
| Revenue YoY | -25.7% | — |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.7M | ||
| Q3 25 | — | $19.0M | ||
| Q2 25 | $18.7M | $20.2M | ||
| Q1 25 | $50.9M | $20.3M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $18.2M | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $41.5M | — |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-154.0K | $-339.4K | ||
| Q1 25 | $23.5M | $-712.4K | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-2.7M | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $13.8M | — |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 40.1% | ||
| Q1 25 | — | 38.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 38.4% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -7.6% | ||
| Q3 25 | — | -3.2% | ||
| Q2 25 | -6.9% | -0.2% | ||
| Q1 25 | 44.4% | -2.0% | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | -2.0% | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | -8.9% | ||
| Q3 25 | — | -6.4% | ||
| Q2 25 | -0.8% | -1.7% | ||
| Q1 25 | 46.2% | -3.5% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -14.6% | ||
| Q2 24 | -26.0% | — | ||
| Q1 24 | 33.3% | — |
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.29 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $3.0M |
| Total DebtLower is stronger | — | $7.3M |
| Stockholders' EquityBook value | $119.9M | $7.3M |
| Total Assets | $175.1M | $33.5M |
| Debt / EquityLower = less leverage | — | 1.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.0M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | $49.0M | $4.7M | ||
| Q1 25 | $47.6M | $1.8M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | $1.8M | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $7.3M | ||
| Q3 25 | — | $8.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | — | $10.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $11.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $7.3M | ||
| Q3 25 | — | $5.9M | ||
| Q2 25 | $119.9M | $5.8M | ||
| Q1 25 | $25.0M | $2.1M | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $2.9M | ||
| Q2 24 | $-31.2M | — | ||
| Q1 24 | $-31.7M | — |
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $33.7M | ||
| Q2 25 | $175.1M | $36.4M | ||
| Q1 25 | $98.5M | $34.1M | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $33.2M | ||
| Q2 24 | $159.2M | — | ||
| Q1 24 | $184.7M | — |
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | 5.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.95× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-855.1K |
| Free Cash FlowOCF − Capex | $-15.8M | $-927.1K |
| FCF MarginFCF / Revenue | -84.6% | -5.0% |
| Capex IntensityCapex / Revenue | 0.1% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $675.4K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-855.1K | ||
| Q3 25 | — | $-308.7K | ||
| Q2 25 | $-15.8M | $1.1M | ||
| Q1 25 | $-21.0M | $1.1M | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | — | $-927.1K | ||
| Q3 25 | — | $-351.3K | ||
| Q2 25 | $-15.8M | $988.6K | ||
| Q1 25 | $-21.2M | $965.3K | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | -5.0% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | -84.6% | 4.9% | ||
| Q1 25 | -41.6% | 4.8% | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.1% | 0.4% | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
HCWC
| Retail Grocery | $17.1M | 91% |
| Food Service Restaurant | $1.7M | 9% |
